Loading…
Lobbying Income
$120K
Filings
12
Unique Clients
2
Active Period
2021–2022
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
VALID Act of 2021
2022 · third_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), telehealth, and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: H.R. 4128
VALID Act of 2021
2022 · third_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), telehealth, and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: S.2209
VALID Act of 2021
2022 · second_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: H.R. 4128
VALID Act of 2021
2022 · second_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: S.2209
VALID Act of 2021
2022 · first_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: H.R. 4128
VALID Act of 2021
2022 · first_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128/S.2209, the VALID Act of 2021), and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: S.2209
VALID Act of 2021
2022 · first_quarter · Client: MOLECULAR TESTING LABS ON BEHALF OF ASCENDANT STRATEGIC PARTNERS
Regulation of diagnostic tests (including H.R. 4128, the VALID Act of 2021), and use of diagnostic tests to improve public health
Client expense: — · Firm income: —
Matched citations: H.R. 4128
TRANSPLANT Act of 2021
2021 · second_quarter · Client: ALLIANCE FOR CELL THERAPY NOW
H.R. 941/S. 288, TRANSPLANT Act of 2021; Appropriations for the National Institutes of Health and support for an outcomes database for adult cellular therapies
Client expense: — · Firm income: —
Matched citations: H.R. 941
TRANSPLANT Act of 2021
2021 · second_quarter · Client: ALLIANCE FOR CELL THERAPY NOW
H.R. 941/S. 288, TRANSPLANT Act of 2021; Appropriations for the National Institutes of Health and support for an outcomes database for adult cellular therapies
Client expense: — · Firm income: —
Matched citations: S. 288
Source: Senate LDA